Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Short Interest Up 88.8% in June

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 83,765 shares, an increase of 88.8% from the June 15th total of 44,358 shares. Based on an average trading volume of 30,721 shares, the short-interest ratio is currently 2.7 days. Approximately 8.4% of the company’s stock are sold short.

Institutional Investors Weigh In On Virtus LifeSci Biotech Clinical Trials ETF

A hedge fund recently bought a new position in Virtus LifeSci Biotech Clinical Trials ETF stock. Worth Asset Management LLC purchased a new stake in shares of Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,093 shares of the company’s stock, valued at approximately $216,000. Worth Asset Management LLC owned about 0.41% of Virtus LifeSci Biotech Clinical Trials ETF as of its most recent SEC filing.

Virtus LifeSci Biotech Clinical Trials ETF Price Performance

Shares of BBC traded down $1.94 during trading hours on Thursday, hitting $49.91. The company had a trading volume of 41,454 shares, compared to its average volume of 24,581. The firm has a fifty day moving average price of $46.34 and a 200-day moving average price of $43.45. Virtus LifeSci Biotech Clinical Trials ETF has a 52-week low of $20.87 and a 52-week high of $54.95.

Virtus LifeSci Biotech Clinical Trials ETF Company Profile

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.